April is a key month for the agriculture calendar, and industry. The soybean harvest is half-way through in Latin America, while in the U.S. and China planting begins. Corn is another crop that will be planted in both countries, and in Europe. At the same time Australia plants winter wheat and a little later India will plant cotton. The high rate of activity around this specific month places great pressure upon agricultural input producers to delivery different nutrients and fertilizers, simultaneously, worldwide. To absorb these market synergies, companies are required to possess a well-oiled production and retail infrastructure. So, is Mosaic (MOS) up to the challenge?
Segments and Seasonal Needs
Not all fertilizers are required simultaneously. These are determined by crop type and soil quality. Hence, nitrogen is applied in great quantities in the U.S. for wheat production, while in Brazil phosphate and potash are the most demanded nutrients by the same crop. Part of the reason for differing application is the salinity of Brazilian soil. On the other hand, China in general demands a great quantity of nitrogen due to soil qualities. Last, phosphate is used worldwide for fruits and farm crops.
Top Insurance Companies To Watch For 2015: Matador Resources Co (MTDR)
Matador Resources Company is an independent energy company engaged in the exploration, development, production and acquisition of oil and natural gas resources in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Its operations are focused primarily on the oil and liquids-rich portion of the Eagle Ford shale play in South Texas and the Wolfcamp and Bone Spring plays in the Permian Basin in Southeast New Mexico and West Texas. The Company also operates in the Haynesville shale and Cotton Valley plays in Northwest Louisiana and East Texas. In addition, it has a large exploratory leasehold position in Southwest Wyoming and adjacent areas of Utah and Idaho where it is testing the Meade Peak shale.
As of December 31, 2012, the Company owned a 100% working interest in approximately 26,900 gross acres and 24,100 net acres in Gonzales, Karnes, LaSalle, Wilson and Zavala Counties and a 50% working interest in approximately 2,800 gross and 1,400 net acres in DeWitt County and are the operator of this acreage. It also owns an approximate 21% working interest in approximately 12,800 gross acres in Atascosa County operated by EOG Resources, Inc.
South Texas
The Company focuses on the exploration and development of its Eagle Ford shale properties in South Texas. During 2012, the Company completed and began producing oil and natural gas from 28 gross/24.5 net operated Eagle Ford shale wells, including 25 gross/23.7 net operated and 3 gross/0.8 net non-operated Eagle Ford shale wells. During 2012, 43% of its daily production, or 3,908 barrels of oil equivalent (BOE) per day, including 3,246 one stock tank barrel (Bbl) of oil per day and 4.0 one million cubic feet of natural gas (MMcf) of natural gas per day, was produced from the Eagle Ford shale in South Texas. During 2012, the Company drilled and completed a total of 32 gross/30.5 net Eagle Ford wells on its operated properties. As of December 31, 2012, its aggregate leasehold int! erests consisted of approximately 42,500 gross acres and 27,900 net acres in the Eagle Ford shale play in Atascosa, DeWitt, Gonzales, Karnes, LaSalle, Wilson and Zavala Counties in South Texas.
Northwest Louisiana and East Texas
During 2012, bout 56% of its average daily production, or 5,042 BOE per day, including 31 Bbl of oil per day and 30.1 MMcf of natural gas per day, was from its leasehold interests in Northwest Louisiana and East Texas. For the year ended December 31, 2012, about 76% of its daily natural gas production, or 26.0 MMcf of natural gas per day, was produced from the Haynesville shale, with another 12%, or 4.1 MMcf of natural gas per day, produced from the Cotton Valley and other shallower formations in this area. As of December 31, 2012, the Company had leasehold and mineral interests in approximately 22,300 gross and 14,200 net acres prospective for the Haynesville shale.
Advisors' Opinion:- [By Ben Levisohn]
Heading into today, Matador Resources (MTDR) had gained 40% so far this year, as the competitor to Anadarko Petroleum (APC) and EOG Resources (EOG) has boosted oil & gas revenue and oil production. Make that 32% after Matador Resources announced a secondary offering.
Hot Forestry Stocks For 2014: Anika Therapeutics Inc.(ANIK)
Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair. Its products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. The company offers orthobiologics products for providing relief from the pain of osteoarthritis, and regenerating damaged tissue, such as cartilage defects; ORTHOVISC for the treatment of osteoarthritis of the knee and various joints; ORTHOVISC mini for the treatment of osteoarthritis in small joints; and MONOVISC, a single injection product used for the treatment of osteoarthritis in various joints. It also provides wound care products that comprise Hyalograft 3D for the regeneration of skin; and Hyalomatrix for the treatment of burns and ulcers. In addition, the company offers AMVISC, AMVISC Plus, STAARVISC-II, Optivisc, and AnikaVisc which are injectable HA products used as viscoelastic agents in o phthalmic surgical procedures, such as cataract extraction and intraocular lens implantation. Further, it provides INCERT, a HA based product for the prevention of post-surgical adhesions; Hyalobarrier and Hyalobarrier Endo, which are post operative adhesion barriers for abdominal indications; and HYVISC, an injectable HA product used for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine osteoarthritis. Additionally, the company offers Merogel, a product used for the treatment of ear, nose, and throat disorders; and provides dermal fillers for facial wrinkles and scar remediation under the ELEVESS and HYDRELLE brand names. It markets its products directly, as well as through a network of distributors primarily in the United States and Europe. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Advisors' Opinion:- [By STOCKPICKR]
Anika Therapeutics (ANIK), together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair in the U.S., Europe, and internationally. This stock closed up 2.1% to $48.86 in Monday's trading session.
Monday's Volume: 1.25 million
Three-Month Average Volume: 347,160
Volume % Change: 272%From a technical perspective, ANIK jumped higher here right above some near-term support at $46 with above-average volume. This spike higher on Monday briefly pushed shares of ANIK into breakout territory, since the stock flirted with some near-term overhead resistance levels at $49.21 to $49.37. Shares of ANIK tagged an intraday high of $51.40, before it closed below that level at $48.86. Market players should now look for a continuation move to the upside in the short-term if ANIK manages to take out Monday's high of $51.36 to its 52-week high of $52.49 with high volume.
Traders should now look for long-biased trades in ANIK as long as it's trending above Monday's low of $47.57 or above $46 and then once it sustains a move or close above $51.36 to $52.49 with volume that hits near or above 347,160 shares. If that move begins soon, then ANIK will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $55 to $60.
Hot Forestry Stocks For 2014: Jazz Pharmaceuticals Inc.(JAZZ)
Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products to meet unmet medical needs. The company markets Xyrem, a sodium oxybate oral solution for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR extended-release capsules for the treatment of obsessive compulsive disorder. Its product candidates under clinical development include JZP-6, a Phase III pivotal clinical trials completed product for the treatment of fibromyalgia; and JZP-8, an intranasal formulation of clonazepam, which has completed Phase II clinical trial for the treatment of acute repetitive seizures in epilepsy and solid oral dosage forms of sodium oxybate. The company sells its products through specialty sales force targeting sleep specialists, psychiatrists, neurologists, and pulmonologists. Jazz Pharmaceuticals, Inc. was founded in 2003 and is headq uartered in Palo Alto, California.
Advisors' Opinion:- [By Selena Maranjian]
For example, consider Lone Pine Capital, founded by Steve Mandel�in 1997. Lone Pine is one of the biggest hedge fund companies, and it has reportedly outperformed�the S&P 500 handily since inception. Its reportable stock portfolio totaled $23 billion�in value as of March 31, 2014. According to its recently released 13F statement, Lone Pine established or added to positions in Jazz Pharmaceuticals plc (NASDAQ: JAZZ ) , SouFun Holdings Ltd (NYSE: SFUN ) , and Valeant Pharmaceuticals International (NYSE: VRX ) .
- [By Philip Springer]
What’s more, earnings estimates for 2014 by Wall Street analysts have increased for seven of the 10 companies over the last three months. Amgen’s are down slightly and those for Celgene and Novo Nordisk are unchanged.
Two of the 10 stocks currently are in the PF Growth Portfolio. Another, Allergan, was sold for a 75 percent long-term gain since its initial recommendation.
As of late February, the 10 stocks profiled carried market capitalizations of roughly $30 billion and up. Here are another four companies to watch: Grifols SA (NSDQ: GRFS), Jazz Pharmaceuticals PLC (NSDQ: JAZZ), Questcor Pharmaceuticals (NSDQ: QCOR) and Salix Pharmaceuticals (NSDQ: SLXP). Each of these four companies is generating rapid revenue and profit growth, and each stock carries a market capitalization of $5 billion or more.
Have a happy and safe Fourth of July weekend! - [By Sean Williams]
What: Shares of biopharmaceutical company Jazz Pharmaceuticals (NASDAQ: JAZZ ) dipped as much as 10% after the company reported its first-quarter results and following regulatory comments with regard to generic competition to its lead drug.
- [By Jake L'Ecuyer]
Shares of Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ) got a boost, shooting up 7.77 percent to $123.65 after the company announced its plans to buy Gentium SpA (NASDAQ: GENT) for around $1 billion.
Hot Forestry Stocks For 2014: Universal Corporation(UVV)
Universal Corporation, together with its subsidiaries, operates as a leaf tobacco merchant and processor worldwide. It engages in selecting, procuring, buying, processing, packing, storing, supplying, shipping, and financing leaf tobacco for sale to, or for the account of, manufacturers of consumer tobacco products. The company processes and/or sells flue-cured and burley tobaccos, dark air-cured tobaccos, and oriental tobaccos; and provides value-added services, including blending, chemical and physical testing of tobacco, just-in-time inventory management, and manufacturing reconstituted sheet tobacco. Its flue-cured, burley, and oriental tobaccos are used principally in the manufacture of cigarettes; and dark air-cured tobaccos are used in the manufacture of cigars, pipe tobacco, and smokeless tobacco products. The company was founded in 1888 and is headquartered in Richmond, Virginia.
Advisors' Opinion:- [By Marc Bastow]
Leaf tobacco supplier Universal Corporation (UVV) raised its quarterly dividend 2% to 51 cents per share, payable on Feb. 10 to shareholders of record as of Jan. 13.
UVV Dividend Yield: 4.06%
- [By Lawrence Meyers]
This isn�� some massive utility service generation billions. As dividend stocks go, it’s a nice, simple business that makes a few million in free cash flow every year and distributes most of it to shareholders as a 3.7% yield … and has been doing so for 41 years.
Universal Corporation (UVV)Dividend yield: 3.9%
Hot Forestry Stocks For 2014: Hemispherx Biopharma Inc (HEB)
Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is a United States Food and Drug Administration (FDA) approved product with an indication for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is a formulation under development targeting influenza. It has three subsidiaries BioPro Corp., BioAegean Corp., and Core BioTech Corp. The Company's foreign subsidiary is Hemispherx Biopharma Europe N.V./S.A.
Ampligen
Ampligen is an experimental drug, which is undergoing clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Over 1,000 patients have participated in the Ampligen clinical trials representing the administration of more than 90,000 doses of this drug. The Company is also engaged in ongoing, experimental studies assessing the efficacy of Ampligen against influenza viruses.
Alferon N Injection
Alferon N Injection is the registered trademark for the Company's injectable formulation of natural alpha interferon. Interferons are a group of proteins produced and secreted by cells to combat diseases. The Company's natural alpha interferon is produced from human white blood cells. Alferon N Injection [Interferon alfa-n3 (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon product.
Alferon LDO (Low Dose Oral)
Alferon LDO [Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)]! is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon and like Alferon N Injection should not cause antibody formation, which is a problem with recombinant interferon. It is an experimental immunotherapeutic that works by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa.
The Company competes with Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Baxter International, Fletcher/CSI, AVANT Immunotherapeutics, AVI BioPharma and Genta.
Advisors' Opinion:- [By MONEYMORNING]
Hemispherix Biopharma Inc. (NYSE: HEB) is a specialty pharmaceutical company. It engages in the clinical development of new drug therapies based on natural immune system enhancing technologies and targets the treatment of viral and immune-based clinical disorders. The Philadelphia, Pa.-headquartered company gained widespread attention over the last several months for its work on flu research. Its flagship products include Alferon N Injection, approved by the FDA for a category of sexually transmitted disease infection. Experimental treatments include Ampligen and Oragens, in development stages for the potential treatment of global viral diseases and disorders of the immune system including human papilloma virus, human immunodeficiency virus, chronic fatigue syndrome, hepatitis, and influenza. Shares have traded as low as $0.18 and as high as $0.55 over the last year. At last check, shares were changing hands around $0.50 on volume of 2 million shares.
Hot Forestry Stocks For 2014: LoJack Corporation(LOJN)
LoJack Corporation provides technology products and services for the tracking and recovery of mobile assets, stolen vehicles, motorcycles, construction equipment, cargo, and people at risk. It offers LoJack Unit, a LoJack System component that consists of a high frequency transponder with a hidden antenna, microprocessor, and power supply, as well as a set of codes unique to the unit; and LoJack Early Warning Unit, an optional component that provides notification to vehicle owners in the event of unauthorized user operating the vehicle. The company also licenses LoJack for Laptops, a system to recover the stolen computers; and LoJack InTransit, a cargo and tracking recovery solution. In addition, it provides LoJack SafetyNet system, which comprises a personal locator unit, a search and rescue receiver used by public safety agencies. The company markets its products to owners of commercial equipment and to consumers through its sales force, telemarketing representatives, di rect mail, and automobile dealers. It operates in the United States, Africa, Latin America, the Caribbean countries, Canada, and Europe. LoJack Corporation was founded in 1978 and is headquartered in Canton, Massachusetts.
Advisors' Opinion:- [By Wallace Witkowski]
Shares of LoJack Corp. (LOJN) �surged 20% to $5.30 on moderate volume after the car-security-system company said an arbitration panel dismissed claims by a Brazilian licensee over a contract dispute.
No comments:
Post a Comment